Flizasertib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally available inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, flizasertib inhibits RIP1-mediated signaling, which may preserve intestinal stem cells (ISCs) and prevent RIP1-mediated gastrointestinal (GI) damage in acute graft-versus-host disease (GvHD). RIP1 plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition.

**Synonyms:** - FLIZASERTIB - GDC 8264 - GDC-8264 - GDC8264 - RG 6287 - RG-6287 - RG6287 - RIP1 Inhibitor GDC-8264 - RIP1 Kinase Inhibitor GDC-8264 - RIPK1 Inhibitor GDC-8264 - RO 7288817 - RO-7288817 - RO7288817